FDA’s Psychedelic Push: Corporate Capture of Mental Health Solutions Amidst Crisis of Care

Indigenous communities have stewarded psychedelic plants for millennia, framing their use within cosmologies of reciprocity, not pharmaceutical efficacy. The FDA’s push to 'ease access' without acknowledging these traditions risks repeating the colonial violence of patenting sacred plants (e.g., ayahuasca’s patent by a US company in 2001) and erasing the ethical frameworks that govern their use. Indigenous leaders like those in the Amazon have warned that corporate exploitation of these medicines will lead to ecological destruction and cultural genocide, as seen with the decimation of peyote populations in Texas due to unregulated harvesting for the 'wellness' industry.

The criminalization of psychedelics in the 1960s was not merely a public health decision but a tool of political repression, targeting Black and Indigenous activists, anti-war movements, and countercultural figures. The current 'psychedelic renaissance' mirrors earlier cycles of medicalization and commodification, such as the 19th-century patent medicine industry or the 20th-century rise of Big Pharma. The FDA’s involvement today echoes its historical role in gatekeeping drugs for profit, as seen with the opioid crisis, where regulatory capture led to mass addiction and death.

In India, traditional Ayurvedic practices use psychedelic-like substances (e.g., *Soma*) within ritual contexts to foster social cohesion and spiritual growth, contrasting with the FDA’s individualistic, biomedical model. In West Africa, the Bwiti tradition of Gabon uses iboga for initiation and healing, emphasizing ancestral connection—a framework absent in Western clinical trials. Meanwhile, in the Pacific Northwest, Indigenous communities like the Nuu-chah-nulth have long used *kinnikinnick* (Arctostaphylos uva-ursi) in ceremonies, but their knowledge is sidelined as Western labs isolate compounds for patenting.

While clinical trials show promise for psychedelics in treating PTSD, depression, and addiction, the research is often underfunded for non-Western modalities and lacks long-term safety data. Studies are dominated by white, male participants, ignoring how psychedelics metabolize differently across populations due to genetic and environmental factors. The FDA’s rush to approve psilocybin and MDMA (e.g., MDMA for PTSD in 2027) prioritizes speed over rigorous, culturally inclusive science, risking repeat of past pharmaceutical failures like the Vioxx scandal.

Artists and spiritual practitioners have long used psychedelics to challenge oppressive systems, from the surrealist movement’s exploration of the subconscious to the Black Arts Movement’s use of altered states for political resistance. The FDA’s commodification of these experiences risks reducing them to 'experiences' rather than tools for systemic transformation. Meanwhile, Indigenous artists like the Shipibo-Conibo’s *kené* designs, which encode ayahuasca visions, are being appropriated by wellness brands without credit or compensation.

If unchecked, the psychedelic industry could replicate the extractive models of Big Pharma, leading to monopolies on sacred plants, ecological collapse, and a two-tiered system where the wealthy access 'healing' while marginalized communities face further criminalization. Scenario modeling suggests that without decolonial frameworks, corporate psychedelics will deepen health inequities, as seen with the privatization of insulin. Conversely, a future grounded in Indigenous-led research and community ownership could redefine mental health as a collective right, not a commodity.

Black and Indigenous communities, who have been disproportionately criminalized for psychedelic use, are now being excluded from the 'healing' narrative despite bearing the brunt of mental health crises. Survivors of the carceral system, who often experience trauma from state violence, are overlooked in favor of Silicon Valley elites seeking 'biohacking' solutions. Grassroots organizations like the *Psychedelic Renaissance Justice Fund* argue that access must begin with decriminalization and reinvestment in community-based care, not venture capital-funded clinics.